Likewise, hepcidin‐directed iron interventions would reach 68% of alpha thalassemia carriers (compared with 40% based on anemia‐screening), although the number of iron replete alpha thalassemia carriers receiving iron would be increased (from 13% to 28%). Here, HAMP is linked to alpha thalassemia spectrum.